Surgical indications and clinical management of benign and malignant follicular thyroid tumors: An algorithmic‑based approach
- Hiroyuki Iwasaki
- Soji Toda
- Daisuke Murayama
- Shin Kato
- Ai Matsui
Affiliations: Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Asahi‑ku, Yokohama, Kanagawa 241‑8515, Japan
- Published online on: December 17, 2020 https://doi.org/10.3892/mco.2020.2194
Copyright: © Iwasaki
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The present study retrospectively reviewed the treatment courses and results of patients with follicular thyroid tumors, including carcinomas. In the 5 year study period from April 2015 to March 2020, 797 patients with differentiated thyroid carcinoma and 128 patients with follicular tumors (FTs) received surgery or treatment for distant metastases and recurrence at the Kanagawa Cancer Center (Japan). Of these patients, 73 that were diagnosed with follicular thyroid carcinoma (FTC) were included in the present study. An algorithm used for the application of treatment strategies was assessed. The aim of the present study was to examine patients with FT or FTC who were treated at the Kanagawa Cancer Center to devise appropriate treatment strategies and to evaluate the various treatment outcomes of FTC. Pre‑diagnostic serum thyroglobulin and thyroid stimulating hormone levels, follow‑up and overall survival (OS) were investigated in the present study. The results revealed that OS was significantly increased in patients with minimally invasive follicular thyroid cancer (MIFTC) compared with widely invasive follicular thyroid cancer (WIFTC) (log‑rank test, P=0.017). Additionally, OS was significantly higher in patients without distant metastasis at the first consultation compared with those initially diagnosed with distant metastasis (log‑rank test, P=0.023). Although all patients without distant metastasis at the first consultation and those with MIFTC are alive, the 10‑year survival rates were 75.3% for patients with WIFTC and 75.6% for those with distant metastasis at the first consultation. The results of the present study suggested that the prognosis of WIFTC was the worst among patients with FTC and distant metastasis, and that total thyroidectomy surgery and radioactive iodine treatment are essential. Additionally, if the disease progresses, prompt inclusion of tyrosine kinase inhibitor therapy is necessary.